Tag: GlobeNewswire

ST. PETERSBURG, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), today announced that it will host an investor webcast presentation on Tuesday, October 13, 2026, at 2:00 p.m. Eastern Time.

During the webcast, Bradford Martz, President and Chief Executive Officer, and Svetlana Castle, Chief Financial Officer, will conduct an introductory presentation covering key aspects of American Coastal’s business, including corporate strategy, business model, and growth initiatives. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

Participants can register here: https://us02web.zoom.us/webinar/register/WN_EnFhLKfxSHOHPdkmKwpuoQ

A link to the webcast will also be available on American Coastal’s investor relations website at https://investors.amcoastal.com.

About American Coastal Insurance Corporation:
American Coastal Insurance Corporation (amcoastal.com) is the holding company of the insurance carrier, American Coastal Insurance Company, which was founded in 2007 for the purpose of insuring Condominium and Homeowner Association properties, Apartments and Assisted Living Facilities in the state of Florida. American Coastal Insurance Company has an exclusive partnership for distribution of Condominium Association properties in the state of Florida with AmRisc Group (amriscgroup.com), one of the largest Managing General Agents in the country specializing in hurricane-exposed properties. American Coastal Insurance Company has earned an “A”, (“Exceptional”) Financial Stability Rating from Demotech and maintains an “A” insurance financial strength rating with a Stable outlook from KBRA. ACIC maintains a “BBB” issuer rating with a Stable outlook from KBRA.

Contact Information:                
Alexander Baty                
Vice President, Finance & Investor Relations, American Coastal Insurance Corporation
investorrelations@amcoastal.com
(727) 425-8076        

Glen Akselrod
President & Founder, Bristol Investor Relations
ga@bristolir.com
(905) 326-1888

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one oral presentation, three rapid-fire oral presentations, and six poster presentations on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026, taking place in Phoenix, Arizona on October 9-12, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Acoramidis is approved as Attruby^® by the U.S. FDA and is approved as BEYONTTRA^® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Oral Presentation:
Association Between the Burden of Cardiovascular-Related Hospitalizations and All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM
Presenter: Quan Bui, M.D., UC San Diego Health, U.S.
Date/time: Saturday, October 10 at 7:45 am MST

Rapid-Fire Oral Presentations:
Real-World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform
Presenter: David Lanfear, M.D., M.S., Chief Scientific Officer of Henry Ford Health, U.S.
Date/time: Sunday, October 11 at 11:30 am MST

Early eGFR Dip Following Acoramidis Initiation is Associated with Reduced Risk of Mortality and Recurrent Cardiovascular-Related Hospitalizations in ATTR-CM
Presenter: Ahmad Masri, M.D., M.S., Oregon Health & Science University, U.S.
Date/time: Sunday, October 11 at 11:12 am MST

Ratio of Serum Transthyretin to NT-proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM
Presenter: James L. Januzzi, M.D., Massachusetts General Hospital, U.S.
Date/time: Sunday, October 11 at 10:45 am MST

Poster Presentations:
Falls and Fractures Drive Increased Hospitalizations and Costs in Patients with Transthyretin Amyloid Cardiomyopathy Compared with Controls
Presenter: Nitasha Sarswat, M.D., University of Chicago, U.S.
Date/time: Friday, October 9 at 6:15 pm MST

Evaluating the Long-Term Effects of Acoramidis on Cardiac Function, Structure, and Amyloid Burden in Transthyretin Amyloid Cardiomyopathy: ASCEND-ATTR
Presenter: Ahmad Masri, M.D., M.S., Oregon Health & Science University, U.S.
Date/time: Saturday, October 10 at 1:45 pm MST

Real-World Burden of Transthyretin Amyloid Cardiomyopathy Disease and Outcomes in Patients on Tafamidis Prior to Initiating Acoramidis
Presenter: Richard Wright, M.D., Pacific Heart Institute, U.S.
Date/time: Saturday, October 10 at 5:45 pm MST

Acoramidis Reduces Risk of Cardiovascular-Related Mortality and Hospitalization in Women with Transthyretin Amyloid Cardiomyopathy
Presenter: Margot Davis, M.D., University of British Columbia, CA
Date/time: Saturday, October 10 at 6:15 pm MST

Acoramidis Preserves Functional Capacity and Quality of Life in p.Val142Ile Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Lily Stern, M.D., Cedars-Sinai Heart Institute, U.S.
Date/time: Sunday, October 11 at 8:15 am MST

Effect of Acoramidis on Heart Failure-Related Health Status Before and After Cardiovascular-Related Hospitalization: Insights from ATTRibute-CM
Presenter: Ahmad Masri, M.D., M.S., Oregon Health & Science University, U.S.
Date/time: Sunday, October 11 at 8:15 am MST

About Attruby^® (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (“Lakefront”) announces that between September 28, 2026, and October 02, 2026, it has repurchased 117,437 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase	Market/MTF	Number of shares	Average price paid (€)	Total (€)	Lowest price paid (€)	Highest price paid (€)
09/ 28/2026	XAMS	17,470	25.77	450,287.50	25.52	26.04
09/28/2026	TQEX	1,388	25.80	35,816.09	25.74	25.98
09/28/2026	CEUX	2,710	25.76	69,813.94	25.64	26.04
09/28/2026	AQEU	1,729	25.72	44,472.47	25.62	25.98
09/29/2026	XAMS	17,899	26.20	469,014.66	26.00	26.34
09/29/2026	TQEX	1,007	26.24	26,421.57	26.16	26.36
09/29/2026	CEUX	4,148	26.26	108,936.44	26.16	26.34
09/29/2026	AQEU	89	26.22	2,333.70	26.16	26.26
09/30/2026	XAMS	16,365	26.23	429,293.23	26.02	26.40
09/30/2026	TQEX	1,532	26.31	40,304.62	26.16	26.34
09/30/2026	CEUX	5,539	26.26	145,479.62	26.12	26.40
09/30/2026	AQEU	134	26.24	3,516.40	26.12	26.28
10/01/2026	XAMS	19,341	25.99	502,662.92	25.64	26.34
10/01/2026	TQEX	572	26.08	14,916.10	26.00	26.16
10/01/2026	CEUX	3,661	26.03	95,289.61	25.68	26.16
10/01/2026	AQEU	136	25.97	3,532.06	25.68	26.04
10/02/2026	XAMS	20,391	25.72	524,372.92	25.36	25.96
10/02/2026	TQEX	277	25.62	7,096.19	25.58	25.70
10/02/2026	CEUX	2,943	25.68	75,586.54	25.34	25.90
10/02/2026	AQEU	106	25.66	2,719.96	25.66	25.66
Total		117,437	25.99	3,051,866.51	25.34	26.40

As of market close on October 02, 2026, Lakefront holds 1,751,031 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
  

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

 Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Attachment

• 20261002 LakefrontEN RNS Announcement

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that it will release its financial results for the third quarter ended September 30, 2026 by press release on Thursday, October 22, 2026 at approximately 7:30 am ET.

The conference call to review these financial results will take place at 11:00 am ET on Thursday, October 22, 2026, and will be hosted by D. Scott Patterson, CEO, and Jeremy Rakusin, CFO. This call is being webcast live at the Company’s website at www.firstservice.com. Participants may register for the call here https://register-conf.media-server.com/register/BI9d7175d9b02f4276bcb50335f8def6ce to receive the dial-in number and their unique PIN. To join the webcast in listen only mode, use this link: https://edge.media-server.com/mmc/p/txwrhwjy. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).

A webcast replay of the call will be available on the Company’s website following the call, in the “Investors” section under the tab “Newsroom”.

About FirstService Corporation

FirstService Corporation is a North American leader in the property services sector, serving its customers through two industry-leading service platforms: FirstService Residential, North America’s largest manager of residential communities; and FirstService Brands, one of North America’s largest providers of essential property services delivered through individually branded company-owned operations and franchise systems.

FirstService generates more than US$5.5 billion in annual revenues and has approximately 30,000 employees across North America. With significant insider ownership and an experienced management team, FirstService has a long-term track record of creating value and superior returns for shareholders. The Common Shares of FirstService trade on the NASDAQ and the Toronto Stock Exchange under the symbol “FSV” and are included in the S&P/TSX 60 index.

For the latest news from FirstService Corporation, visit Firstservice.com.

COMPANY CONTACTS:

D. Scott Patterson
Chief Executive Officer
(416) 960-9566

Jeremy Rakusin
Chief Financial Officer
(416) 960-9566

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 60,000 shares of its common stock. The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted pursuant to the Company’s 2026 Inducement Plan, with a grant date of October 1, 2026, as an inducement material to the new employee entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of such employee’s start date, with the remainder of the option vesting in 36 equal monthly installments thereafter, subject to continued employment on each vesting date.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

Lille, Oct. 06, 2026 (GLOBE NEWSWIRE) — Top Wealth Group Holding Limited (NASDAQ: TWG)(“Top Wealth” or the “Company”), today announced it received a notification letter dated October 2, 2026 from The Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

According to the letter, the closing bid price of the Company’s listed securities was below US$1.00 per share for the last 30 consecutive business days, i.e. from August 20, 2026 to October 1, 2026.

The notice has no immediate effect on the Company’s listing or the trading of its securities on Nasdaq. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a 180-calendar day compliance period, or until March 31, 2027, to regain compliance. If at any time during this period the closing bid price of the Company’s securities is at least US$1.00 for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the bid price requirement.

If the Company does not regain compliance by the end of the initial compliance period, it may be eligible for an additional 180-calendar-day extension, subject to meeting the continued listing standards for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market (excluding the bid price requirement). In that case, the Company must also provide written notice of its intention to cure the deficiency, including through a potential reverse stock split if necessary.

The Company intends to monitor the closing bid price of its securities and will consider all available options to regain compliance within the applicable grace periods.

About Top Wealth Group Holding Limited

Top Wealth Group Holding Limited is a holding company incorporated in the Cayman Islands, with all operations carried out through its operating subsidiary in Hong Kong, Top Wealth Group (International) Limited. The Company specializes in supplying premium-class sturgeon caviar, and its caviar and caviar products are endorsed with the Convention on International Trade in Endangered Species of Wild Fauna and Flora (“CITES”) permits. The Company supplies caviar to customers under customer brand labels (i.e. private labeling), and also sells under its own brand, “Imperial Cristal Caviar,” which has continuously achieved significant sales growth since its launch.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in verbal statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

Top Wealth Group Holding Limited
Investor Relations
Email: ir@topwealth.cc

Sponsor fee waiver extended for an additional 12 months to provide zero-cost exposure and staking yield potential for U.S. investors

NEW YORK, October 6, 2026 – 21shares, one of the world’s largest issuers of cryptocurrency exchange traded funds (ETFs), today announced a 12-month extension of the sponsor fee waiver for the 21shares Ethereum Staking ETF (TETH).

Originally introduced alongside the integration of staking features in October 2025, the 100% sponsor fee waiver will now remain in effect for an additional year through October 8, 2027. 

Through staking, the Trust participates in Ethereum’s network validation process, enabling investors to benefit from the yield-generating potential of the protocol. The net staking reward (after the deduction of fees and expenses) for TETH, as of October 1, 2026 is 2.65%. 

“Extending our fee waiver for an additional 12 months underscores our commitment to providing investors with cost-efficient access to Ethereum,” said Duncan Moir, President and Chief Investment Officer at 21shares. “By combining a 100% fee waiver with the yield-generating power of network staking, we are continuing to pass the native benefits of blockchain technology directly back to our investors at zero cost.”

The fee waiver extension applies automatically to all current and prospective shareholders, with no action required from investors.

For more information on TETH, please visit https://www.21shares.com/en-us/products-us/teth.

About 21shares

21shares is one of the world’s leading cryptocurrency exchange traded product (ETP) providers and offers one of the largest suites of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralized finance. 21shares listed the world’s first physically-backed crypto ETP in 2018, building a seven-year track record of creating crypto ETPs that are listed on some of the biggest, most liquid securities exchanges globally. Backed by a specialized research team, proprietary technology, and deep capital markets expertise, 21shares delivers innovative, simple and cost-efficient investment solutions.

21shares is a subsidiary of FalconX, one of the world’s largest digital asset prime brokers. 21shares maintains independent operations from FalconX while strategically leveraging the resources and reach of FalconX to accelerate its mission and unlock new growth. For more information, please visit www.21shares.com.

Media Contact
Audrey Belloff: audrey.belloff@21shares.com
Alethea Jadick: ajadick@sloanepr.com

Important Information

The 21shares Ethereum Staking ETF (TETH) (referred to as the “Trust”) is not registered under the Investment Company Act of 1940 (the “40 Act”) and therefore is not subject to the same regulations and protections as 40 Act registered ETFs and mutual funds. Investing involves significant risk, including possible loss of principal. An investment in the Trust is subject to a high degree of risk and heightened volatility and not suitable for all investors. The Trust is not suitable for an investor who cannot afford the loss of the entire investment. An investment in the Trust is not a direct investment in ETH.

Investing involves significant risk, including the possible loss of principal. There is no assurance that the Trust will generate a profit for investors.

Ethereum is a relatively new asset class, and the market for these assets is subject to rapid changes and uncertainty. Ethereum is largely unregulated and these investments may be more susceptible to fraud and manipulation than more regulated investments.

Must be preceded or accompanied by the prospectus for TETH (here).

The Trust participates in staking a portion of its holdings in order to generate additional rewards. Staking involves committing assets to support the operations of a blockchain and, in return, may provide rewards to the Trust. While staking can potentially enhance returns, it also introduces additional risks, including operational, technological, regulatory, and counterparty risks. Staking Ethereum introduces several risks, including the possibility of losing staked Ethereum through penalties, slashing, or inactivity leaks if validators behave poorly, go offline, or violate protocol rules. Staked Ethereum can also be locked for long and unpredictable periods due to activation and exit queues, creating liquidity constraints and making it harder to meet redemptions. Because staking depends heavily on third-party providers, operational failures, outages, cybersecurity breaches, or mismanagement by these providers could lead to lost assets or reduced rewards. Rewards themselves are uncertain and can fluctuate based on network conditions, validator performance, governance changes, commission rates, and downtime. Additionally, staking may create conflicts of interest if operators are incentivized to stake more Ethereum than is prudent, increasing liquidity risk.

Ethereum is subject to unique and substantial risks, including significant price volatility, lack of liquidity, and theft. The value of an investment in the Trust could decline significantly and without warning, including to zero. Ethereum is subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in supply and demand, and other factors. There is no assurance that Ethereum will maintain its value over the long-term.

Staking rewards earned by the Trust accrue to the Trust’s assets and are reflected in NAV over time. The Trust will not distribute staking rewards directly to shareholders. Shareholders may nonetheless incur tax liability on staking income without receiving a corresponding distribution. The treatment of staking in a grantor trust for U.S. federal income tax purposes is still developing and may change. 

Failure by the Trust’s Custodians to exercise due care in the safekeeping of the Trust’s underlying digital assets, as applicable, could result in a loss to the Trust. Shareholders cannot be assured that a Custodian will maintain adequate insurance with respect to the digital assets held by the Custodian on behalf of the Trust.

The Trust is not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of its underlying digital assets, as applicable. An investment in the Trust is not a direct investment in Ethereum. Investors will also forgo certain rights conferred by owning these digital assets directly. Shares of a Trust are generally bought and sold at market price (not NAV) and are not individually redeemed from the Trust. Only Authorized Participants may trade directly with a Trust and only in large blocks of Shares called “creation units.” Your brokerage commissions will reduce returns.

Shares in the Trust are not FDIC insured, may lose value, and have no bank guarantee.

The Marketing Agent for the Trust is Foreside Global Services, LLC. 21shares US LLC is the Sponsor to the Trust. 21shares is not affiliated with Foreside Global Services, LLC. FalconX is not affiliated with Foreside Global Services, LLC.

© 2026 21shares US LLC. No part of this material may be reproduced in any form, or referred to in any other publication, without written permission.

###

Live Platform Enables Users to Purchase AI Tokens and Access Supported Models, Including OpenAI GPT, Kimi, Meta Llma and Qwen

KUALA LUMPUR, Malaysia, Oct. 06, 2026 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that VGAIN Compute, an AI token platform developed by its subsidiary V Gallant Limited (“V Gallant”), has gone live, marking another step in the Company’s expansion into AI infrastructure, GPU computing and AI services.

VGAIN Compute enables users to purchase AI tokens to access supported large language models (LLMs), including OpenAI GPT models associated with ChatGPT, Kimi, Meta Llama and Qwen. By bringing multiple AI models into a single access platform, VGAIN Compute is designed to serve a broad range of use cases, including content generation, coding, research, business applications and workflow automation.

The launch gives V Gallant a direct, customer-facing platform for AI services while creating a commercial layer that can complement the Company’s broader investments in AI computing infrastructure.

Connecting AI Infrastructure with AI Demand

VCI Global’s AI strategy spans both the infrastructure required to power AI workloads and the platforms through which users consume AI services.

Through V Gallant, the Company is developing capabilities across AI computing and infrastructure while building commercial channels that connect computing capacity with end-user demand. VGAIN Compute represents an important component of this approach, providing a usage-based platform through which customers can purchase AI tokens and access supported AI models.

As the platform develops, V Gallant expects to evaluate opportunities to expand its model catalogue, introduce additional enterprise-focused capabilities and support increasingly sophisticated AI workloads.

The platform is also designed to support developers and businesses exploring agentic AI applications, where AI models can be used to execute tasks, coordinate processes and automate workflows. Such applications can generate recurring demand for AI inference, the computing process through which AI models produce responses and outputs.

“Our objective is to build an AI business that connects infrastructure with real-world customer demand,” said Victor Hoo, Group Chief Executive Officer and Executive Chairman of VCI Global. “With VGAIN Compute now live, we have established a customer-facing platform through which users can purchase AI tokens and access a range of leading AI models. This gives us a foundation to develop the services side of our AI strategy as we continue expanding our computing capabilities.”

The launch of VGAIN Compute provides V Gallant with an initial platform from which to develop a broader AI services ecosystem.

Going forward, the Company expects to focus on expanding the supported model catalogue, increasing platform adoption, developing enterprise use cases and aligning additional computing capacity with customer requirements.

For VCI Global, the opportunity extends beyond providing access to individual AI models. The Company sees potential across AI inference, enterprise automation, agentic AI and other compute-intensive workloads, with infrastructure expansion to be guided by customer demand, hardware availability and project economics.

About VCI Global Limited

VCI Global Limited (NASDAQ: VCIG) is an AI-native operating platform designed to scale and optimize businesses through centralized intelligence, data, and capital discipline.

The Company operates a platform-based model in which subsidiaries, affiliates, and portfolio companies plug into VCI Global’s centralized AI, data, governance, and capital allocation systems, enabling faster execution, improved capital efficiency, and scalable growth across multiple industries.

VCI Global’s platform centralizes AI-enabled execution, standardized KPI frameworks, financial and governance controls, and strategic capital allocation, while operating businesses focus on revenue generation, customer relationships, and local execution.

The Company maintains exposure across advisory, AI, and digital infrastructure, digital assets, energy, automotive, and consumer sectors, and continuously evaluates opportunities to scale, spin off, divest, or discontinue businesses based on performance, scalability, and return on capital.

VCI Global’s platform-centric approach is designed to enhance productivity, improve IPO readiness, and unlock long-term value through disciplined growth and selective capital deployment.

For more information on the Company, please log on to https://v-capital.co/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements are based only on our current beliefs, expectations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission (“SEC”). The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

For media queries, please contact:

VCI GLOBAL LIMITED
enquiries@v-capital.co

Live Platform Enables Users to Purchase AI Tokens and Access Supported Models, Including OpenAI GPT, Kimi, Meta Llma and Qwen

KUALA LUMPUR, Malaysia, Oct. 06, 2026 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that VGAIN Compute, an AI token platform developed by its subsidiary V Gallant Limited (“V Gallant”), has gone live, marking another step in the Company’s expansion into AI infrastructure, GPU computing and AI services.

VGAIN Compute enables users to purchase AI tokens to access supported large language models (LLMs), including OpenAI GPT models associated with ChatGPT, Kimi, Meta Llama and Qwen. By bringing multiple AI models into a single access platform, VGAIN Compute is designed to serve a broad range of use cases, including content generation, coding, research, business applications and workflow automation.

The launch gives V Gallant a direct, customer-facing platform for AI services while creating a commercial layer that can complement the Company’s broader investments in AI computing infrastructure.

Connecting AI Infrastructure with AI Demand

VCI Global’s AI strategy spans both the infrastructure required to power AI workloads and the platforms through which users consume AI services.

Through V Gallant, the Company is developing capabilities across AI computing and infrastructure while building commercial channels that connect computing capacity with end-user demand. VGAIN Compute represents an important component of this approach, providing a usage-based platform through which customers can purchase AI tokens and access supported AI models.

As the platform develops, V Gallant expects to evaluate opportunities to expand its model catalogue, introduce additional enterprise-focused capabilities and support increasingly sophisticated AI workloads.

The platform is also designed to support developers and businesses exploring agentic AI applications, where AI models can be used to execute tasks, coordinate processes and automate workflows. Such applications can generate recurring demand for AI inference, the computing process through which AI models produce responses and outputs.

“Our objective is to build an AI business that connects infrastructure with real-world customer demand,” said Victor Hoo, Group Chief Executive Officer and Executive Chairman of VCI Global. “With VGAIN Compute now live, we have established a customer-facing platform through which users can purchase AI tokens and access a range of leading AI models. This gives us a foundation to develop the services side of our AI strategy as we continue expanding our computing capabilities.”

The launch of VGAIN Compute provides V Gallant with an initial platform from which to develop a broader AI services ecosystem.

Going forward, the Company expects to focus on expanding the supported model catalogue, increasing platform adoption, developing enterprise use cases and aligning additional computing capacity with customer requirements.

For VCI Global, the opportunity extends beyond providing access to individual AI models. The Company sees potential across AI inference, enterprise automation, agentic AI and other compute-intensive workloads, with infrastructure expansion to be guided by customer demand, hardware availability and project economics.

About VCI Global Limited

VCI Global Limited (NASDAQ: VCIG) is an AI-native operating platform designed to scale and optimize businesses through centralized intelligence, data, and capital discipline.

The Company operates a platform-based model in which subsidiaries, affiliates, and portfolio companies plug into VCI Global’s centralized AI, data, governance, and capital allocation systems, enabling faster execution, improved capital efficiency, and scalable growth across multiple industries.

VCI Global’s platform centralizes AI-enabled execution, standardized KPI frameworks, financial and governance controls, and strategic capital allocation, while operating businesses focus on revenue generation, customer relationships, and local execution.

The Company maintains exposure across advisory, AI, and digital infrastructure, digital assets, energy, automotive, and consumer sectors, and continuously evaluates opportunities to scale, spin off, divest, or discontinue businesses based on performance, scalability, and return on capital.

VCI Global’s platform-centric approach is designed to enhance productivity, improve IPO readiness, and unlock long-term value through disciplined growth and selective capital deployment.

For more information on the Company, please log on to https://v-capital.co/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements are based only on our current beliefs, expectations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission (“SEC”). The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

For media queries, please contact:

VCI GLOBAL LIMITED
enquiries@v-capital.co

MARIETTA, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) — Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) announced today that it plans to release its results for the third quarter ended September 30, 2026, on Thursday, October 29, 2026, before the opening of regular trading on the NASDAQ Stock Market. The Company will provide a supplemental investor presentation in the Investors section of its website at investors.donegalgroup.com, concurrently with its earnings press release.

At approximately 8:30 am EDT on Thursday, October 29, 2026, the Company will make available in the Investors section of its website a pre-recorded audio webcast featuring management commentary by Kevin Burke, President and Chief Executive Officer; Jeffrey Miller, Executive Vice President and Chief Financial Officer; and select members of the senior management team. Management will address questions they receive in advance in their prepared remarks. Questions for consideration should be submitted via e-mail to investors@donegalgroup.com by 5:00 pm EDT on Thursday, October 15, 2026.

About Donegal Group Inc.

Donegal Group Inc. is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty lines of insurance in 21 Mid-Atlantic, Midwestern, Southern and Southwestern states. Donegal Mutual Insurance Company and its insurance subsidiaries conduct business together with the insurance subsidiaries of Donegal Group Inc. as the Donegal Insurance Group. The Donegal Insurance Group has an A.M. Best rating of A (Excellent).

The Class A common stock and Class B common stock of Donegal Group Inc. trade on the NASDAQ Global Select Market under the symbols DGICA and DGICB, respectively. The Company is focused on several primary strategies, including achieving sustained excellent financial performance, advancing its operational and digital capabilities, capitalizing on opportunities to grow profitably and providing superior experiences to its agents, customers and employees.

Investor Relations Contact

Jeremy Hellman, Vice President, The Equity Group Inc.
Phone: (212) 836-9626
E-mail: jhellman@theequitygroup.com